News
ANTH
0.0001
NaN%
--
Weekly Report: what happened at ANTH last week (0715-0719)?
Weekly Report · 3d ago
Weekly Report: what happened at ANTH last week (0708-0712)?
Weekly Report · 07/15 11:09
Weekly Report: what happened at ANTH last week (0701-0705)?
Weekly Report · 07/08 11:10
Weekly Report: what happened at ANTH last week (0624-0628)?
Weekly Report · 07/01 11:11
Weekly Report: what happened at ANTH last week (0617-0621)?
Weekly Report · 06/24 11:18
Weekly Report: what happened at ANTH last week (0610-0614)?
Weekly Report · 06/17 11:10
Weekly Report: what happened at ANTH last week (0603-0607)?
Weekly Report · 06/10 11:12
Weekly Report: what happened at ANTH last week (0527-0531)?
Weekly Report · 06/03 11:15
Weekly Report: what happened at ANTH last week (0520-0524)?
Weekly Report · 05/27 11:19
Weekly Report: what happened at ANTH last week (0513-0517)?
Weekly Report · 05/20 11:13
Weekly Report: what happened at ANTH last week (0506-0510)?
Weekly Report · 05/13 11:23
Weekly Report: what happened at ANTH last week (0429-0503)?
Weekly Report · 05/06 11:30
Weekly Report: what happened at ANTH last week (0422-0426)?
Weekly Report · 04/29 11:38
Weekly Report: what happened at ANTH last week (0415-0419)?
Weekly Report · 04/22 11:26
Weekly Report: what happened at ANTH last week (0408-0412)?
Weekly Report · 04/15 11:17
Weekly Report: what happened at ANTH last week (0401-0405)?
Weekly Report · 04/08 11:22
Weekly Report: what happened at ANTH last week (0325-0329)?
Weekly Report · 04/01 11:19
Weekly Report: what happened at ANTH last week (0318-0322)?
Weekly Report · 03/25 11:23
Weekly Report: what happened at ANTH last week (0311-0315)?
Weekly Report · 03/18 11:21
Weekly Report: what happened at ANTH last week (0304-0308)?
Weekly Report · 03/11 11:17
More
Webull provides a variety of real-time ANTH stock news. You can receive the latest news about Anthera Pharmace through multiple platforms. This information may help you make smarter investment decisions.
About ANTH
Anthera Pharmaceuticals, Inc. (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod. Sollpura is a non-porcine investigational Pancreatic Enzyme Replacement Therapy (PERT) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (EPI), often seen in patients with cystic fibrosis and other conditions. Blisibimod targets B-cell activating factor (BAFF), which has been shown to be elevated in a range of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), or lupus, Immunoglobulin A nephropathy (IgA) nephropathy, lupus nephritis and others.